DXT
DEAD

Serial Number

90042373

Owner

DOMPE' FARMACEUTICI SPA

Attorney

Kristen McCallion

Filing Date

Jul 8, 2020

Add to watchlist:

No watchlists yet
View on USPTO

DXT Trademark

Serial Number: 90042373

DXT is a trademark filed by DOMPE' FARMACEUTICI SPA on July 8, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

DOMPE' FARMACEUTICI SPA (8 trademarks)

Via S. Martino della Battaglia, 12

Entity Type: 09

Trademark Details

Filing Date

July 8, 2020

Registration Date

Not Registered

Published for Opposition

December 15, 2020

Goods & Services

downloadable computer software for use in identifying new drugs; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable computer application software for mobile phones, namely, software for use in identifying new drugs; downloadable computer software using artificial intelligence for use in identifying new drugs; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems

Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceutical preparations; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of rare ocular disorders or diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold preparations; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treatment of rare tissue and organ transplantation-related diseases and conditions; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems

software as a service (SAAS) services featuring software using artificial intelligence for use in identifying new drugs; providing a website featuring non-downloadable software using artificial intelligence for use in identifying new drugs; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of virtual reality software for medical teaching

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 6, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 5, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 4, 2022 EXRA
SOU EXTENSION 1 GRANTED
Feb 2, 2022 EX1G
SOU EXTENSION 1 FILED
Feb 2, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 2, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 3, 2021 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 24, 2021 ETOP
POST PUBLICATION AMENDMENT - ENTERED
Jun 3, 2021 CHPB
ASSIGNED TO PETITION STAFF
Jun 2, 2021 APET
TEAS/EMAIL CORRESPONDENCE ENTERED
May 25, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 25, 2021 CRFA
TEAS POST PUBLICATION AMENDMENT RECEIVED
Mar 29, 2021 EPPA
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 8, 2021 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Dec 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 25, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 9, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 6, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 20, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 16, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 6, 2020 NWOS
NEW APPLICATION ENTERED
Jul 11, 2020 NWAP